13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001856083
Total reported value
$6.9B
$6.9B
55 檔
33.9%
During the Q4 2025 filing period, Deep Track Capital, LP (CIK: 0001856083) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $6.9B across 55 reported positions.
Deep Track Capital, LP executed strategic sector rebalancing during Q4 2025, establishing 17 new positions while fully exiting 18 holdings and trimming 15 positions.
In terms of portfolio concentration, the top 5 core holdings (including XBI, IMVT, GH) accounted for 33.9% of total reported equity market value during Q4 2025.
Top New Position Initiated
XBI
市值: $1.2B
Top Position Liquidated / Trimmed
AKRO
前期市值: $190.0M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 21.74% | -20.86% | EXIT | |
| 2 | IMVT | Immunovant Inc | Stock-Other | 5.22% | +0.56% | +18.48% | |
| 3 | GH | Guardant Health Inc | Stock-Healthcare | 5.10% | +2.37% | -32.60% | |
| 4 | GPCR | Structure Therapeutics Inc | Stock-Other | 5.10% | +0.33% | -2.47% | |
| 5 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 4.39% | -0.76% | +0.13% | |
| 6 | DVAX | Dynavax Technologies CORP | Stock-Other | 4.31% | — | — | |
| 7 | CYTK | Cytokinetics Inc | Stock-Healthcare | 3.78% | -0.61% | -22.40% | |
| 8 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 3.74% | -0.55% | +27.78% | |
| 9 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.47% | -2.98% | EXIT | |
| 10 | PCVX | Vaxcyte Inc | Stock-Other | 3.29% | -0.44% | +33.33% | |
| 11 | MAZE | Maze Therapeutics Inc | Stock-Other | 3.14% | -0.08% | +7.53% | |
| 12 | VERA | Vera Therapeutics Inc | Stock-Other | 2.55% | -0.20% | — | |
| 13 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.44% | +1.69% | +9153.30% | |
| 14 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.40% | +0.15% | -55.36% | |
| 15 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.38% | +1.12% | +16.17% | |
| 16 | MBX | Mbx Biosciences Inc | Stock-Other | 1.83% | +0.05% | +3.17% | |
| 17 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.75% | +0.09% | -32.36% | |
| 18 | GRAL | Grail Inc | Stock-Healthcare | 1.56% | +0.37% | — | |
| 19 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.40% | +0.51% | -53.07% | |
| 20 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 1.33% | +0.23% | — | |
| 21 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.24% | -0.81% | +11.33% | |
| 22 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.17% | +1.04% | -18.58% | |
| 23 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.10% | -1.02% | EXIT | |
| 24 | CRMD | Cormedix Inc | Stock-Other | 1.09% | +0.02% | +954.82% | |
| 25 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.08% | +0.03% | — | |
| 26 | ALKS | Alkermes plc | Stock-Healthcare | 1.00% | +0.98% | — | |
| 27 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.92% | -0.11% | +32.50% | |
| 28 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.92% | +0.92% | -4.96% | |
| 29 | CMPS | Compass Pathways PLC | Stock-Other | 0.90% | +1.40% | -6.68% | |
| 30 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.89% | -2.05% | EXIT | |
| 31 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.83% | -0.59% | EXIT | |
| 32 | VSTM | Verastem Inc | Stock-Other | 0.79% | -0.18% | — | |
| 33 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.78% | +0.45% | +7.72% | |
| 34 | GERN | Geron CORP | Stock-Other | 0.77% | -0.77% | EXIT | |
| 35 | ✓ | Engene Holdings Inc | Stock-Other | 0.70% | -0.49% | EXIT | |
| 36 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 0.67% | -0.75% | EXIT | |
| 37 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.55% | -0.92% | EXIT | |
| 38 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 0.55% | -0.09% | — | |
| 39 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 0.40% | — | +11.77% | |
| 40 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.39% | +0.97% | +68.75% | |
| 41 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 0.36% | -0.03% | +346.66% | |
| 42 | ATAI | AtaiBeckley Inc. | Stock-Other | 0.34% | — | — | |
| 43 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.29% | — | -69.46% | |
| 44 | COGT | Cogent Biosciences Inc | Stock-Other | 0.29% | +0.50% | — | |
| 45 | HELP | Cybin Inc | Stock-Other | 0.27% | -0.10% | EXIT | |
| 46 | CNTX | Context Therapeutics Inc | Stock-Other | 0.19% | -0.26% | — | |
| 47 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.11% | — | — | |
| 48 | BHVN | Biohaven Ltd. | Stock-Other | 0.10% | — | — | |
| 49 | ✓ | Crescent Biopharma Inc. | Stock-Other | 0.10% | -0.14% | EXIT | |
| 50 | ALGS | Aligos Therapeutics Inc | Stock-Other | 0.07% | -0.01% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BMRN | Biomarin Pharmaceutical Inc | +2.4% | +9153.30% | Add |
| 2 | GPCR | Structure Therapeutics Inc | +1.8% | -2.47% | Trim |
| 3 | CRMD | Cormedix Inc | +0.9% | +954.82% | Add |
| 4 | IMVT | Immunovant Inc | +0.8% | +18.48% | Add |
| 5 | NRIX | Nurix Therapeutics Inc | +0.8% | +16.17% | Add |
| 6 | AXSM | Axsome Therapeutics Inc | +0.7% | +27.78% | Add |
| 7 | MBX | Mbx Biosciences Inc | +0.3% | +3.17% | Add |
| 8 | MAZE | Maze Therapeutics Inc | +0.3% | +7.53% | Add |
| 9 | PCVX | Vaxcyte Inc | +0.3% | +33.33% | Add |
| 10 | ✓ | Engene Holdings Inc | +0.3% | +95.48% | Add |
| 11 | XFOR | X4 Pharmaceuticals Inc | +0.3% | +346.66% | Add |
| 12 | DYN | Dyne Therapeutics Inc | +0.2% | +32.50% | Add |
| 13 | HELP | Cybin Inc | +0.1% | +85.43% | Add |
| 14 | TNGX | Tango Therapeutics Inc | +0.1% | +68.75% | Add |
| 15 | CNTX | Context Therapeutics Inc | 0% | — | Unchanged |
| 16 | DVAX | Dynavax Technologies CORP | -0.1% | — | Unchanged |
| 17 | ALGS | Aligos Therapeutics Inc | -0.1% | — | Unchanged |
| 18 | ✓ | Crescent Biopharma Inc. | -0.1% | — | Unchanged |
| 19 | BRD1EUR | Mind Medicine Mindmed Inc | -0.1% | +11.77% | Add |
| 20 | LBRX | Lb Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 21 | ORKA | Oruka Therapeutics Inc | -0.3% | -18.58% | Trim |
| 22 | BCAX | Bicara Therapeutics Inc | -0.3% | +7.72% | Add |
| 23 | CMPS | Compass Pathways PLC | -0.4% | -6.68% | Trim |
| 24 | RAPT | Rapt Therapeutics Inc | -0.5% | -85.30% | Trim |
| 25 | ANIP | Ani Pharmaceuticals Inc | -0.5% | +6.15% | Add |
| 26 | CLDX | Celldex Therapeutics Inc | -0.5% | -4.96% | Trim |
| 27 | IMCR | Immunocore Holdings Plc-adr | -0.6% | +11.33% | Add |
| 28 | TARS | Tarsus Pharmaceuticals Inc | -0.6% | +0.13% | Add |
| 29 | BBIO | Bridgebio Pharma Inc | -0.6% | -32.49% | Trim |
| 30 | GERN | Geron CORP | -0.8% | -20.89% | Trim |
| 31 | 430 | Terns Pharmaceuticals Inc | -1% | -89.74% | Trim |
| 32 | XENE | Xenon Pharmaceuticals Inc | -1.1% | -69.46% | Trim |
| 33 | APLSUSD | Apellis Pharmaceuticals Inc | -1.6% | -3.13% | Trim |
| 34 | VRDN | Viridian Therapeutics Inc | -1.8% | -53.07% | Trim |
| 35 | OCUL | Ocular Therapeutix Inc | -2.1% | -32.36% | Trim |
| 36 | GH | Guardant Health Inc | -2.1% | -32.60% | Trim |
| 37 | CYTK | Cytokinetics Inc | -2.8% | -22.40% | Trim |
| 38 | IONS | Ionis Pharmaceuticals Inc | -4.6% | -55.36% | Trim |
| 39 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 40 | AKRO | Akero Therapeutics Inc | — | EXIT | Sold out |
| 41 | VERA | Vera Therapeutics Inc | — | NEW | New buy |
| 42 | ETNBGBP | 89bio Inc | — | EXIT | Sold out |
| 43 | PTGX | Protagonist Therapeutics Inc | — | EXIT | Sold out |
| 44 | GRAL | Grail Inc | — | NEW | New buy |
| 45 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 46 | ALKS | Alkermes plc | — | NEW | New buy |
| 47 | EXK | Exact Sciences CORP | — | EXIT | Sold out |
| 48 | 260 | Centessa Pharmaceuticals-adr | — | NEW | New buy |
| 49 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 50 | VSTM | Verastem Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Deep Track Capital, LP reported a total U.S. public equity portfolio value of $6.9B across 55 disclosed positions in Q4 2025.
During Q4 2025, Deep Track Capital, LP's top holdings by market value included XBI (21.7%)、IMVT (5.2%)、GH (5.1%). The largest single position, XBI, represented 21.7% of total portfolio value.
In Q4 2025, Deep Track Capital, LP made 68 total portfolio adjustments, initiating 17 new buys, adding to 18 positions, trimming 15 holdings, and fully liquidating 18 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.